Dataset from A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009183
下载链接
链接失效反馈官方服务：
资源简介：
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral
activity of an investigational regimen including FDA approved HIV drugs in HIV-infected
pediatric subjects, ages 4 weeks to < 2 years old.
创建时间：
2024-11-27
